Capital One analysts revealed the firm’s top picks for 2024 in the biotechnology sector. Based on disclosed catalysts for 2024 and expectations around downside versus upside risks, the firm’s three biotech analysts each selected two picks they believe should be of focus to investors this year. The top picks are Arvinas (ARVN), Kodiak Sciences (KOD), Protagonist Therapeutics (PTGX), Repare Therapeutics (RPTX), Day One Biopharmaceuticals (DAWN) and Immunocore (IMCR).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas Appoints Jared Freedberg as General Counsel
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Poised to Outperform in 2024
- 3 Best Stocks to Buy Now, 12/20/2023, According to Top Analysts
- Arvinas upgraded to Overweight from Equal Weight at Wells Fargo
- Arvinas files to sell 16.39M shares of common stock for holders